Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767)
07/2003
07/16/2003CN1430596A New gamma selective retinoids
07/16/2003CN1430521A Solid dispersion system of Pranlukast with improved dissolution, and the preparing method thereof
07/16/2003CN1430518A Use of lactobacillus casei in immunostimulatory peptides
07/16/2003CN1430508A Novel composition
07/16/2003CN1429834A Fructus gleditsiae total saponin, its preparation method and use in preparation of medicine
07/16/2003CN1429602A Medicine for treating throat disease and its preparation method
07/16/2003CN1429601A Heat-Clearing away heat and toxic material and subsidence of swelling powder
07/16/2003CN1429578A Medicinal atomization liquid for treating pharyngitis and its manufacturing process
07/16/2003CN1429558A Mannosan peptide injection and its preparation and use method
07/16/2003CN1429556A Muscle strong agent and anti-inflammatory agent
07/16/2003CN1114604C Bicyclic aryl carboxamides and their therapeutic use
07/16/2003CN1114597C Quinoline derivs
07/16/2003CN1114426C Powder for treating throat disease and preparing process thereof
07/15/2003US6593472 NK-1 receptor active amine oxide prodrugs
07/15/2003US6593357 Treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
07/15/2003US6593354 Substituted benzoxazole compounds
07/15/2003US6593352 2-phenylalkylaminobenzoic acid containing substituted benzylsufamoyl group; useful for treating cardiovascular disorders, and for preserving or storing a transplant for surgery
07/15/2003US6593351 Carboxylic acid substituted heterocycles, derivatives thereof and methods of use
07/15/2003US6593347 Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use
07/15/2003US6593335 Disease than can be ameliorated with a potassium channel opener in a host mammal, comprising administering to the mammal in need thereof a therapeutically effective amount of the compound of claim 1; said disease is epilepsy, Raynaud's
07/15/2003US6593333 Substituted anilino-quinazoline (or quinoline) compounds and use thereof
07/15/2003US6593327 Compounds and compositions as protease inhibitors
07/15/2003US6593292 Amidine and/or guanidine substituted peptoid and drug conjugates for drug delivery across endo/epithelial tissue
07/15/2003US6592887 Mixture containing water soluble polymer
07/15/2003US6592848 Ready to use aerosol packages
07/10/2003WO2003056013A1 TGF-β-SPECIFIC COVALENTLY CLOSED ANTISENSE MOLECULE
07/10/2003WO2003055983A2 Targeted retrograde gene delivery to motor neurons
07/10/2003WO2003055913A2 Secreted protein
07/10/2003WO2003055912A2 Secreted proteins
07/10/2003WO2003055884A1 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-carboxamide derivatives, their preparation and therapeutic use
07/10/2003WO2003055882A1 Pyrrolopyrimidines as phosphodiesterase vii inhibitors
07/10/2003WO2003055876A1 Chemokine receptor binding heterocyclic compounds with enhanced efficacy
07/10/2003WO2003055875A1 Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor
07/10/2003WO2003055874A1 Bipyridinyl derivatives as a highly selective cyclooxygenase-2 inhibitor
07/10/2003WO2003055863A1 Novel alkansulfonamides as endothelin antagonists
07/10/2003WO2003055558A1 Polyherbal composition for the treatment of bronchial asthma and the process
07/10/2003WO2003055547A1 Medicament dispenser
07/10/2003WO2003055481A1 Organ fibrosis inhibitors
07/10/2003WO2003055474A1 Treatment of faecal incontinence and other conditions with 1r, 2s-methoxamine
07/10/2003WO2003055447A2 Heterocyclic acridone inhibitors of impdh enzyme
07/10/2003WO2003055440A2 Compositions and methods for the treatement of immune related diseases
07/10/2003WO2003055335A1 Modified methionine rich food products and process for their manufacture
07/10/2003WO2003050119A3 Urea substituted imidazopyridines
07/10/2003WO2003043905A3 Pharmaceutical product with an adsorbent
07/10/2003WO2003035107A8 Enzyme inhibitors for inactivating allergens
07/10/2003WO2003004511A3 Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals
07/10/2003WO2002092625A3 Moraxella(branhamella) catarrhalis antigens
07/10/2003WO2002072788A3 Chronic obstructive pulmonary disease-related immunglobulin derived proteins, compositions, methods and uses
07/10/2003WO2002059267A3 Constitutively desensitized g protein-coupled receptors
07/10/2003WO2002013845A3 Inflammation related g-protein coupled receptor
07/10/2003WO2002000730A9 Pd-l2 molecules: novel pd-1 ligands and uses therefor
07/10/2003WO2001098269A3 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
07/10/2003US20030131370 Disruption of the glutathione S-transferase-Omega-1 gene
07/10/2003US20030130508 3,5-bis(trifluoromethyl)phenylmethylene-substituted derivatives of nicotamide or pyridinylaminocarbonyl compounds; used to treat disorders of the central nervous system such as anxiety, depression and psychosis.
07/10/2003US20030130355 Serotonin/noradrenaline reuptake inhibitors (N-(1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutyl)-N,N-dimethylamine; dietetics; side effects reduction
07/10/2003US20030130352 Such as 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E for treatment of cystic fibrosis
07/10/2003US20030130333 Combination product and methods of use
07/10/2003US20030130309 Antiinflammatory agents; rheumatic diseases
07/10/2003US20030130292 Immunosuppressants; autoimmune disease; skin disorders; Crohn's disease; antidiabetic agents; anticancer agents; antiarthritic agents
07/10/2003US20030130283 CRF receptor antagonists and methods relating thereto
07/10/2003US20030130282 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
07/10/2003US20030130277 Pyrazoloquinolinone derivatives as protein kinase C inhibitors
07/10/2003US20030130273 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
07/10/2003US20030130271 1,3-Diheterocyclic metalloprotease inhibitors
07/10/2003US20030130266 Pharmacological treatment for sleep apnea
07/10/2003US20030130263 Mixture of two antihistamines; sustained release
07/10/2003US20030130254 Respiratory system disorders; antihistamines; antiarthritic agents
07/10/2003US20030130232 Amidine derivatives, the preparation and use thereof as medicaments with LTB4 antagonistic effect
07/10/2003US20030130218 Methods of stimulating phagocytosis
07/10/2003US20030130203 Sleep disorders
07/10/2003US20030130201 Mixture with ascorbic acid, proline and lysine
07/10/2003US20030130200 Tripeptide or tetrapeptide
07/10/2003US20030130182 Secreted and transmembrane polypeptides and nucleic acids encoding the same
07/10/2003US20030130176 Spary drying dispersion; antiinflammatory agents; antihistamines; lung diseases
07/10/2003US20030130168 Reverse-turn mimetics and methods relating thereto
07/10/2003US20030129606 Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
07/10/2003US20030129251 Polynucleotide of an immunostimulatory sequence linked to a biodegradable microcarrier
07/10/2003US20030129245 Mixing micronised formoterol its salt or solvate with a pre-micronised carrier/diluent at low energy, agglomerating and spheronisation or adding a coarse carrier/diluent; treating respiratory system disorders
07/10/2003US20030129242 Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
07/10/2003US20030129237 Multiparticulate modified release composition
07/10/2003US20030129205 Inducing presensitization of immune system towards an immunogen carrying lymphocytes epitope homologous to allergen; immunosuppressants
07/10/2003US20030129141 Dispersable dry powder; controlling moisture concentration, particle size; in situ drug delivery
07/10/2003US20030129134 Method of monitoring neuroprotective treatment
07/10/2003US20030129129 Prevention, therapy disease; forming tritiated water; calibration
07/10/2003CA2471306A1 Secreted proteins
07/10/2003CA2470666A1 Secreted protein
07/10/2003CA2458751A1 Compositions and methods for the treatement of immune related diseases
07/09/2003EP1325931A1 Inhibitors of human neutrophil elastase
07/09/2003EP1325904A1 Novel aliphatic compounds, process for their preparation and their usage
07/09/2003EP1325903A1 2,3-diphenylpropionic acid derivatives or their salts, medicines or cell adhesion inhibitors containing the same, and their usage
07/09/2003EP1325765A1 Combinations of Formoterol and Mometasone Furoate for Asthma
07/09/2003EP1325137A2 Truncated phosphodiesterase-7 polypeptides
07/09/2003EP1325122A2 Modulation of the transcription of pro-inflammatory gene products
07/09/2003EP1325117A2 Lipid metabolism enzymes
07/09/2003EP1325032A2 Nectin polypeptides, polynucleotides, methods of making and use thereof
07/09/2003EP1325009A2 Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
07/09/2003EP1325008A1 Piperazine derivatives
07/09/2003EP1325007A2 Hexahydropyrazino[1'2':1,6]-pyrido[3,4-b]indole-1,4-dione derivatives for the treatment of cardiovascular disorders and erectile disfunction
07/09/2003EP1325001A1 Anticholinergic agents that can be used as medicaments and method for the production thereof
07/09/2003EP1324994A2 Tricyclic compounds and uses thereof